home / stock / cingw / cingw articles

CINGW Articles, Cingulate Inc. Warrants

Stock Information
Company Name: Cingulate Inc. Warrants
Stock Symbol: CINGW
Market: NASDAQ
Website: cingulate.com
Menu
CINGW CINGW Quote CINGW Short CINGW News CINGW Articles CINGW Message Board
Get CINGW Alerts

News, Short Squeeze, Breakout and More Instantly...
Cingulate Announces Exercise of Warrants for $1.86 Million Gross Proceeds | Benzinga

KANSAS CITY, Kan., June 28, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (the "Company") (NASDAQ:CING), a biopharmaceutical company utilizing its pro...
Cingulate and ADHD Expert Dr. Ann Childress, MD to Participate in Benzinga All Live Access Event | Benzinga

KANSAS CITY, Kan., June 25, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precisi...

Peter J. Werth, Successful Pharma Entrepreneur, Philanthropist, Cingulate Investor and Board Member, to be Featured with Chairman and CEO Shane J. Schaffer on Benzinga All Live Access | Benzinga

KANSAS CITY, Kan., April 30, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precis...

Cingulate to Participate in Planet MicroCap Showcase: Vegas 2024 | Benzinga

KANSAS CITY, Kan., April 16, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precis...
Cingulate to Participate in Benzinga All Live Access Event | Benzinga

KANSAS CITY, Kan., March 19, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precis...

Cingulate to Attend DCAT Week 2024 in New York City | Benzinga

KANSAS CITY, Kan., March 06, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Preci...

Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to its Board of Directors | Benzinga

KANSAS CITY, Kan., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precis...
Cingulate Announces Pricing of $7.5 Million Public Offering | Benzinga

KANSAS CITY, Kan., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING) ("Cingulate," the "Company," "we," "our" or "us"), a biopharma...

Werth Family Investment Associates Converts Remaining $3.3M of Debt and Accrued Interest into Cingulate Equity at Premium to Market | Benzinga

KANSAS CITY, Kan., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING) (Cingulate), a biopharmaceutical company utilizing its proprie...

Cingulate to Host CNS Key Opinion Leader Panel in New York City | Benzinga

KANSAS CITY, Kan., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precis...
Next 10